FDA Approves Once-Monthly Hereditary Angioedema Drug

By News Health
3 months Ago

(MedPage Today) — Anti-factor XIIa biologic garadacimab (Andembry) got the FDA greenlight for use in preventing hereditary angioedema (HAE) attacks in adult and pediatric patients ages 12 years and older, CSL announced.
Garadacimab is the only…

Source link : https://www.medpagetoday.com/washington-watch/fdageneral/116122

Author :

Publish date : 2025-06-17 20:32:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Physicians' Group Recommends All Adults Get a COVID Booster

‘Great Migration’ involves far fewer wildebeest than we had thought

'Super Tough Decision': Top CDC Official Reflects on Her Resignation

'This Will Get People Killed': Experts Alarmed by CDC's Sharp Political Turn

Drug Combo Fails to Cut Fracture Risk in Brittle Bone Disease

BP-Friendly Diet; Globe PFA System OK'd; Cardiologist Under Fire Over British Royals